Publications by authors named "Atefeh Behkar"
Traffic Inj Prev
November 2024
Article Synopsis
- The study compared the effectiveness of the No-apnea questionnaire (NAQ) and the STOP-BANG questionnaire (SBQ) in screening for obstructive sleep apnea (OSA) among commercial drivers.
- In a sample of 581 drivers, the NAQ identified a significantly higher percentage (65.7%) as high risk for OSA compared to the SBQ (17.7%).
- The results showed poor correlation between the two screening tools, indicating that they yield different diagnostics outcomes for assessing OSA risk.
Curr J Neurol
January 2024
Article Synopsis
- COVID-19 has been linked to an increase in mucormycosis and subsequently septic cavernous sinus thrombosis, prompting a study on the effects of anticoagulation (AC) in patients with COVID-related complications.
- In this retrospective study involving 29 patients, researchers compared health outcomes, including mortality and neurological sequelae, between those who received AC and those who did not.
- The findings indicated no significant differences in recovery or mortality rates between AC receivers and non-receivers, but due to the small sample size, the results remain inconclusive regarding the effectiveness of AC in this context.*
Head Face Med
September 2024
Article Synopsis
- Migraine affects 10% of the global population and is a major cause of disability, with myofascial trigger points (MTrPs) linked to both migraines and psychological issues like anxiety and depression.
- A study with 68 migraine patients aimed to explore the relationship between MTrPs, migraine-related disability, anxiety, and depression by utilizing standard scales for assessments.
- Results revealed a positive correlation between the number of MTrPs and headache severity, and patients with higher anxiety levels had more MTrPs, suggesting that addressing both physical and mental health issues could lead to better migraine treatment approaches.
Article Synopsis
- The study explores the effect of rituximab on cognitive impairment in relapsing-remitting multiple sclerosis (RRMS) patients, as there are no approved medications specifically for this issue.
- In a year-long trial involving 28 RRMS patients, cognitive assessments were conducted at baseline, six months, and twelve months after treatment, using various tests including the MACFIMS and Beck Depression Inventory.
- Results showed significant improvements in certain cognitive functions, particularly in verbal learning and memory, but did not note significant changes in other cognitive tests, suggesting that rituximab can prevent cognitive decline but further research is needed for more conclusive results.
